

E1
Cont
particles], provided that each of said [substance] one or more substances is selected from the group consisting of a C₈-C₁₆ fatty acid, a salt of such a fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, and an alkyl saccharide.

43. (Amended) The composition of claim 42, wherein the composition contains only [said active compounds] (A) and (B).

E2
Cont
44. (Amended) The composition of claim 42, wherein the composition contains[, in addition to said active compounds,] a non-hygrosopic additive which is a pharmaceutically acceptable carrier.

E3
45. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of [a] sodium, potassium and lysine [salt] salts of caprylic acid (C₈), capric acid (C₁₀), lauric acid (C₁₂), and myristic acid (C₁₄).

E4
49. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of an alkyl glucoside and alkyl maltoside.

50. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of a decyl glucoside, dodecyl glucoside, decyl maltoside, and dodecyl maltoside.

51. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of [a] sodium and potassium [salt] salts of glycyrrhizine acid.

E⁴ cont
52. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of decanoyl carnitine, lauryl carnitine, myristoyl carnitine, and palmitoyl carnitine.

E⁵
53. (Amended) The composition of claim 42, in which at least 50 % of [the dry powder] the total mass of (A) and (B) consists of [(a)] primary particles having a diameter of between 1 and 6 microns [or (b) agglomerates of such particles].

54. (Amended) The composition of claim 42, wherein the ratio of (A) to (B) [in said mixture] is in the range of 9:1 to 1:1.

60. (Amended) The composition of claim 42, wherein said polypeptide is selected from the group consisting of a growth factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade[, that exerts its pharmacological effect systemically].

63. (Amended) A [pharmaceutical] composition [comprising a mixture of active compounds] consisting essentially of (A) a [pharmaceutically active] polypeptide [and], (B) [a phospholipid which enhances] one or more phospholipids that enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said [mixture] composition being in the form of a [non-hygroscopic] dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of [said active compounds] (A) and (B) consists of [(a)] primary particles having a diameter of up to about 10 microns [or (b) agglomerates of such particles].

64. (Amended) The composition of claim 63, wherein the composition contains only said [active compounds] polypeptide and said one or more phospholipids.

65. (Amended) The composition of claim 63, wherein the composition contains[, in addition to said active compounds,] a

non-hygroscopic additive which is a pharmaceutically acceptable carrier.

66. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is selected from the group consisting of diacylphosphatidylcholine, diacylphosphatidylglycerol, diacylphosphatidylethanolamine, diacylphosphatidylinositol, and diacylphosphatidylserine.

67. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is dioctanoylphosphatidylglycerol or dioctanoylphosphatidylcholine.

68. (Amended) The composition of claim 63, in which at least 50% of the [dry powder] total mass of said polypeptide and said one or more phospholipids consists of [(a)] primary particles having a diameter of between 1 and 6 microns [or (b) agglomerates of such particles].

69. (Amended) The composition of claim 63, wherein the ratio of (A) to (B) [in said mixture] is in the range of 9:1 to 1:1.

72. (Amended) The composition of claim 63, wherein said polypeptide is selected from the group consisting of a growth

E⁹
cont factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade[, that exerts its pharmacological effect systemically].

75. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is a single-chain phospholipid.

E¹⁰ 76. (Amended) The composition of claim 75, wherein [said phospholipid] at least one of said one or more phospholipids is selected from the group consisting of lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine.

77. (Amended) The composition of claim 75, wherein [said phospholipid] at least one of said one or more phospholipids is palmitoylphosphatidylglycerol or palmitoylphosphatidylcholine.

78. (Amended) The composition of claim 75, wherein the composition contains only [said active compounds] (A) and (B).

79. (Amended) The composition of claim 75, wherein the composition contains[, in addition to said active compounds,] a